Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.
Symbyax is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of about $82 million in the United States, based on IMS sales data.
Click here to receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org